Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12194049-B2
Publication Date
2025-01-14
Expiration Date
Abstract
The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.
Core Innovation
The invention relates to a method of treating infection with carbapenem antibiotic-resistant Acinetobacter baumannii by administering a therapeutically effective amount of a composition comprising sulbactam and ceftazidime. The ceftazidime amount in the sulbactam/ceftazidime composition is 10%-90% by mass of the amount of sulbactam.
The problem addressed is the treatment of infections caused by carbapenem antibiotic-resistant Acinetobacter baumannii, including conditions where resistance involves carbapenems and, in some embodiments, ceftazidime. The disclosed composition is configured so that ceftazidime is present within a defined low-to-high mass proportion relative to sulbactam rather than equimolar or unrestricted mixing.
The disclosure further supports an unexpected beneficial therapeutic effect for sulbactam/ceftazidime compared with carbapenem plus sulbactam. The described experimental support includes enhanced cumulative inhibition and long-term microbicidal activity, and in an animal pneumonia model sulbactam/low-proportion ceftazidime improves survival compared to 1:1 and to meropenem plus sulbactam.
The disclosure provides possible mechanisms to explain the results, including that ceftazidime may protect sulbactam from β-lactamases or affect efflux, and that limiting excess ceftazidime PBP occupation may preserve sulbactam action.
Claims Coverage
The document includes one independent claim directed to a treatment method for carbapenem antibiotic-resistant Acinetobacter baumannii using a sulbactam/ceftazidime composition. The independent claim is characterized by a single core quantitative relationship: ceftazidime is 10%-90% by mass relative to sulbactam.
Ceftazidime mass proportion relative to sulbactam for treating carbapenem-resistant Acinetobacter baumannii
A method of treating infection with carbapenem antibiotic-resistant Acinetobacter baumannii by administering a therapeutically effective amount of a composition comprising sulbactam and ceftazidime, wherein the amount of ceftazidime is 10%-90% by mass of the amount of sulbactam.
Therapeutically effective sulbactam/ceftazidime composition administration to a subject
Administering a therapeutically effective amount of a composition comprising sulbactam and ceftazidime to a subject in need thereof for treating the carbapenem antibiotic-resistant Acinetobacter baumannii infection.
Overall claim coverage centers on administering a sulbactam/ceftazidime composition to treat carbapenem antibiotic-resistant Acinetobacter baumannii, with ceftazidime present at 10%-90% by mass relative to sulbactam. Dependent claims refine this by specifying sub-ranges for the mass proportion, daily dose ranges for sulbactam, non-oral formulation, injection or inhalant embodiment aspects, and additional resistance conditions such as ceftazidime resistance in the target organism.
Stated Advantages
Unexpectedly effective therapy superior to carbapenem plus sulbactam.
Enhanced cumulative microbial inhibition and long-term microbicidal activity.
Improved survival in an animal pneumonia model compared to 1:1 sulbactam/ceftazidime and compared to meropenem plus sulbactam.
Documented Applications
Treating infections caused by carbapenem antibiotic-resistant Acinetobacter baumannii using a therapeutically effective sulbactam/ceftazidime composition with ceftazidime at a defined mass proportion relative to sulbactam.
Interested in licensing this patent?